Eli Lilly and Company (LLY) shares rose 0.62% to $1,176.80 on Friday, gaining $7.20 during the trading session, after the company announced new Phase 3b findings showing broader biological responses from combined treatment with Taltz and Zepbound. The results expand earlier evidence of improved psoriasis symptoms and weight reduction among adults living with psoriasis and obesity. The announcement centered on the company's TOGETHER-PsO clinical program, which pairs the anti-inflammatory medicine Taltz with the weight-management therapy Zepbound.

Stronger Phase 3b Findings for Taltz and Zepbound

Eli Lilly released new exploratory findings from its TOGETHER-PsO Phase 3b clinical trial, which examined two existing prescription medicines. Researchers compared the combined use of Taltz and Zepbound against Taltz alone in adults with moderate-to-severe plaque psoriasis. The study also included participants with obesity or overweight alongside at least one additional weight-related medical condition. Phase 3b studies are typically used to gather additional data on questions extending beyond a treatment's core later-stage testing, such as specific patient populations or biological mechanisms.

The latest analysis identified broader changes in proteins and genes among participants receiving both medicines compared with those on Taltz alone. By Week 36, researchers identified changes involving 482 proteins in the combination group, compared with 140 in the group taking only Taltz. Similarly, gene expression changes affected 467 genes with combined treatment, against only 16 genes with Taltz alone. Molecular measures like these allow researchers to track how treatment affects biological activity beyond outward measures such as skin clearance.

According to the pharmaceutical company's newly released findings, these biological differences appeared as early as Week 12. Researchers also identified stronger reductions in inflammatory immune activity among participants receiving both treatments over the study period. Eli Lilly presented the findings at the 2026 Fall Clinical Dermatology Conference in Las Vegas.

Combined Treatment Improves Skin Clearance and Weight Reduction

The new findings build on earlier clinical results showing better treatment outcomes among participants receiving Taltz alongside Zepbound. At Week 36, the combination delivered superior skin and meaningful weight reduction compared with Taltz alone. Furthermore, participants maintained or improved these clinical benefits through Week 52, according to Eli Lilly's previously reported findings.

The analysis also examined neutrophils, immune cells that play an important role in the body's inflammatory response. Researchers found that combined treatment produced greater changes in inflammatory pathways associated with these cells. Changes in certain neutrophil-related markers partly explained the additional improvement in psoriasis severity scores among participants receiving medicines.

The TOGETHER-PsO trial included 274 adults across multiple clinical research centers, with participants divided equally between two treatment groups. One group received Taltz alone, while the other received Taltz and Zepbound through injections under the skin. Both groups also received guidance on reducing calorie intake and increasing physical activity throughout the clinical study.

Eli Lilly Expands Research Into Psoriasis and Obesity

Eli Lilly designed the study to examine the relationship between metabolic health and inflammatory skin conditions. Approximately 61% of Americans with psoriasis also experience obesity or overweight alongside another weight-related medical condition, according to the company. That degree of overlap makes treatment approaches addressing weight and inflammation together relevant to a large share of people living with psoriasis. The findings add to research into how treatments targeting different biological processes may influence both conditions. Researchers assessed whether addressing weight and inflammation together could lead to broader clinical benefits.

Taltz works by blocking interleukin-17A, an immune signaling protein involved in inflammation and several related inflammatory conditions. Zepbound targets GIP and GLP-1 receptors, helping regulate appetite and support weight management in eligible adults. Because the two medicines act through different biological pathways, their combined clinical effects formed the basis of the investigation. Studying medicines that are already prescribed individually allowed the combination to be evaluated using therapies with existing safety records.

Eli Lilly reported that the combination's safety findings matched the established safety profiles of the individual medicines. The exploratory results do not establish a new approved indication for using the medicines together. Under standard regulatory practice, a new indication would require its own clinical evidence and regulatory review. The company continues examining the relationship between immune and metabolic processes as researchers assess broader approaches to psoriasis management.

Source: Blockonomi